Susquehanna International Group, LLP Gamida Cell Ltd. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$0.04 - $0.46 $4,368 - $50,232	109,200 Added 118.82%	201,100 $8,000
Q4 2023 Feb 14, 2024	BUY	$0.25 - $1.02 $1,350 - $5,508	5,400 Added 6.24%	91,900 $37,000
Q3 2023 Nov 14, 2023	SELL	$0.85 - $1.87 $449,395 - $988,669	-528,700 Reduced 85.94%	86,500 $89,000
Q2 2023 Aug 11, 2023	BUY	$0.73 - $2.37 $285,868 - $928,092	391,600 Added 175.13%	615,200 $1.19 Million
Q1 2023 May 16, 2023	BUY	$0.68 - $1.71 $127,024 - $319,428	186,800 Added 507.61%	223,600 $181,000
Q4 2022 Feb 14, 2023	SELL	$1.15 - $2.1 $37,030 - $67,620	-32,200 Reduced 46.67%	36,800 $47,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.39 $105,570 - $233,910	69,000 New	69,000 $110,000
Q1 2022 May 16, 2022	BUY	$2.22 - $4.47 $54,168 - $109,068	24,400 Added 29.26%	107,800 $447,000
Q2 2021 Aug 11, 2021	SELL	$5.85 - $8.33 $449,865 - $640,577	-76,900 Reduced 47.97%	83,400 $535,000
Q1 2021 May 17, 2021	BUY	$7.8 - $12.43 $1.25 Million - $1.99 Million	160,300 New	160,300 $1.3 Million

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.